Teva Announces FDA Approval of Inhaled Antibiotic Tobramycin

The generic version should be launched in late November. Tobramycin is an antibiotic drug used to fight bacterial infections. It is currently marketed under the names of Tobrex or Tobi. The drug is inhaled into the lungs using a nebulizer. A 28 day supply costs $2400, wow so there’s a ton of room for savings here.

Teva Pharmaceutical Industries Ltd. (TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI^® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI^® had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013.